GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Intercept Pharmaceuticals Inc. (ICPT) [hlAlert]

Rating:
Outperform
ICPT
up 279.59 %

Intercept Pharmaceuticals Inc. (ICPT) rated Outperform with price target $375 by Oppenheimer

Posted on: Wednesday,  Nov 18, 2015  10:25 AM ET by Oppenheimer

Oppenheimer rated Outperform Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) on 11/18/2015. Previously Oppenheimer rated Outperform Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) on 07/11/2013.,
when the stock price was $49.88. Since then, Intercept Pharmaceuticals Inc. has gained 279.59% as of 01/28/2016's recent price of $189.34.
If you would have followed the previous Oppenheimer's recommendation on ICPT, you would have gained 279.59% of your investment in 931 days.



OppenheimerFunds, Inc. has been helping investors achieve their financial goals since 1960. We are one of the nation's largest and most respected asset management companies. At OppenheimerFunds, we believe that in order for you to reach your financial goals, your investments must perform. That is why investment excellence—over the long term and across the range of our products—is our highest priority. OppenheimerFunds and its controlled affiliates offer a broad range of products and services to individuals, corporations and institutions, including mutual funds, separately managed accounts, investment management for institutions, hedge fund products, qualified retirement plans and subadvisory investment-management services.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/18/2015 10:25 AM Buy
None
168.78 375.00
as of 8/27/2015
1 Week down  -19.92 %
1 Month down  -28.51 %
3 Months down  -38.33 %
1 YTD up  177.29 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/14/2014 9:25 AM Buy
None
462.26 525.00
3/14/2014 9:25 AM Buy
None
462.26 525.00
1/10/2014 8:25 AM Buy
None
445.83 360.00
10/1/2013 8:25 AM Buy
None
69.25 94.00
7/11/2013 8:25 AM Buy
None
49.88 64.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy